Across TCGA pan-cancer cohorts, DYNLL2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DYNLL2 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher DYNLL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DYNLL2 expression acts as an unfavorable survival marker.
SKCM are the cancer types where DYNLL2 Mutation most reproducibly stratifies survival.